Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAVO + fluoxetine hydrochloride mimetic
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Classical Binding Small Molecules → Small Molecules
- Administration
- Oral (for SSRI-mimetic), Topical/inhalation (for Cavo Patch)[4]
01
Overview
CAVO + fluoxetine hydrochloride mimetic is a combination therapy consisting of Cang Ai Volatile Oil (CAVO), an aromatherapy agent, and a compound that acts as a mimetic of fluoxetine hydrochloride. Fluoxetine is a well-established selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. The "mimetic" component suggests the use of a substance designed to replicate the pharmacological effects of fluoxetine rather than using the original molecule itself. This combination has been studied for its potential in treating mild to moderate depression[4]. The mechanism involves increasing serotonin levels in the brain via inhibition of its reuptake (for the SSRI-mimicking component), while CAVO may provide additional therapeutic benefit through aromatherapy.
- Other names
- CAVO and fluoxetine hydrochloride mimeticCang Ai Volatile Oil plus fluoxetine hydrochloride mimetic
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on CAVO + fluoxetine hydrochloride mimetic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAVO + fluoxetine hydrochloride mimetic.